Diffuse large-cell lymphoma of the testis

Carlo Tondini, Andrés J M Ferreri, Licia Siracusano, Pinuccia Valagussa, Roberto Giardini, Irene Rampinelli, Gianni Bonadonna

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Purpose: To evaluate clinical outcome of patients with testicular diffuse large-cell lymphoma treated with conventional-dose systemic chemotherapy. Patients and Methods: This study is a retrospective analysis of adult patients with testicular diffuse large-cell lymphoma who were treated with a doxorubicin-based chemotherapy regimen at our institution, the Istituto Nazionale Tumori of Milan. Twenty-nine assessable patients, with a median age of 61 years, were identified. Sixteen patients had limited stage (Ann Arbor stage I/II) disease, whereas 13 patients had a testicular mass and distant organ involvement (Ann Arbor stage IV). Patients were retrospectively classified according to the International Prognostic Index. Results: After a median follow-up of 82 months, 22 patients presented disease progression and 22 patients had died. Actuarial median time to treatment failure and overall survival were 44 and 41 months for patients with limited stage and 9 and 16 months for patients with advanced stage, respectively. Eight patients failed initial treatment, and 14 patients relapsed from clinical remission after a median disease-free time of 17 months (range, 6 to 98 months). Median survival time after progression of lymphoma was 5 months (range, 0 to 22 months). In nine (41%) of the 22 failing patients, the initial site of relapse was either the CNS or the contralateral testis; the remaining patients experienced relapse in multiple extranodal sites. Conclusion: Poor pregnosis of patients with diffuse large-cell lymphoma calls for more effective treatment strategies, such as high-dose chemotherapy programs for younger patients or specifically designed chemotherapy regimens for patients not suitable for high-dose treatment, with the purpose to provide control of both systemic disease and disease of the CNS and contralateral testis. The potential benefit of contralateral testicular irradiation has to be taken into account in the treatment planning.

Original languageEnglish
Pages (from-to)2854-2858
Number of pages5
JournalJournal of Clinical Oncology
Volume17
Issue number9
Publication statusPublished - Sep 1999

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Testis
Drug Therapy
Recurrence
Survival
Central Nervous System Diseases
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tondini, C., Ferreri, A. J. M., Siracusano, L., Valagussa, P., Giardini, R., Rampinelli, I., & Bonadonna, G. (1999). Diffuse large-cell lymphoma of the testis. Journal of Clinical Oncology, 17(9), 2854-2858.

Diffuse large-cell lymphoma of the testis. / Tondini, Carlo; Ferreri, Andrés J M; Siracusano, Licia; Valagussa, Pinuccia; Giardini, Roberto; Rampinelli, Irene; Bonadonna, Gianni.

In: Journal of Clinical Oncology, Vol. 17, No. 9, 09.1999, p. 2854-2858.

Research output: Contribution to journalArticle

Tondini, C, Ferreri, AJM, Siracusano, L, Valagussa, P, Giardini, R, Rampinelli, I & Bonadonna, G 1999, 'Diffuse large-cell lymphoma of the testis', Journal of Clinical Oncology, vol. 17, no. 9, pp. 2854-2858.
Tondini C, Ferreri AJM, Siracusano L, Valagussa P, Giardini R, Rampinelli I et al. Diffuse large-cell lymphoma of the testis. Journal of Clinical Oncology. 1999 Sep;17(9):2854-2858.
Tondini, Carlo ; Ferreri, Andrés J M ; Siracusano, Licia ; Valagussa, Pinuccia ; Giardini, Roberto ; Rampinelli, Irene ; Bonadonna, Gianni. / Diffuse large-cell lymphoma of the testis. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 9. pp. 2854-2858.
@article{5aef4a29d50d4b2bac0c4c1aba88a88b,
title = "Diffuse large-cell lymphoma of the testis",
abstract = "Purpose: To evaluate clinical outcome of patients with testicular diffuse large-cell lymphoma treated with conventional-dose systemic chemotherapy. Patients and Methods: This study is a retrospective analysis of adult patients with testicular diffuse large-cell lymphoma who were treated with a doxorubicin-based chemotherapy regimen at our institution, the Istituto Nazionale Tumori of Milan. Twenty-nine assessable patients, with a median age of 61 years, were identified. Sixteen patients had limited stage (Ann Arbor stage I/II) disease, whereas 13 patients had a testicular mass and distant organ involvement (Ann Arbor stage IV). Patients were retrospectively classified according to the International Prognostic Index. Results: After a median follow-up of 82 months, 22 patients presented disease progression and 22 patients had died. Actuarial median time to treatment failure and overall survival were 44 and 41 months for patients with limited stage and 9 and 16 months for patients with advanced stage, respectively. Eight patients failed initial treatment, and 14 patients relapsed from clinical remission after a median disease-free time of 17 months (range, 6 to 98 months). Median survival time after progression of lymphoma was 5 months (range, 0 to 22 months). In nine (41{\%}) of the 22 failing patients, the initial site of relapse was either the CNS or the contralateral testis; the remaining patients experienced relapse in multiple extranodal sites. Conclusion: Poor pregnosis of patients with diffuse large-cell lymphoma calls for more effective treatment strategies, such as high-dose chemotherapy programs for younger patients or specifically designed chemotherapy regimens for patients not suitable for high-dose treatment, with the purpose to provide control of both systemic disease and disease of the CNS and contralateral testis. The potential benefit of contralateral testicular irradiation has to be taken into account in the treatment planning.",
author = "Carlo Tondini and Ferreri, {Andr{\'e}s J M} and Licia Siracusano and Pinuccia Valagussa and Roberto Giardini and Irene Rampinelli and Gianni Bonadonna",
year = "1999",
month = "9",
language = "English",
volume = "17",
pages = "2854--2858",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Diffuse large-cell lymphoma of the testis

AU - Tondini, Carlo

AU - Ferreri, Andrés J M

AU - Siracusano, Licia

AU - Valagussa, Pinuccia

AU - Giardini, Roberto

AU - Rampinelli, Irene

AU - Bonadonna, Gianni

PY - 1999/9

Y1 - 1999/9

N2 - Purpose: To evaluate clinical outcome of patients with testicular diffuse large-cell lymphoma treated with conventional-dose systemic chemotherapy. Patients and Methods: This study is a retrospective analysis of adult patients with testicular diffuse large-cell lymphoma who were treated with a doxorubicin-based chemotherapy regimen at our institution, the Istituto Nazionale Tumori of Milan. Twenty-nine assessable patients, with a median age of 61 years, were identified. Sixteen patients had limited stage (Ann Arbor stage I/II) disease, whereas 13 patients had a testicular mass and distant organ involvement (Ann Arbor stage IV). Patients were retrospectively classified according to the International Prognostic Index. Results: After a median follow-up of 82 months, 22 patients presented disease progression and 22 patients had died. Actuarial median time to treatment failure and overall survival were 44 and 41 months for patients with limited stage and 9 and 16 months for patients with advanced stage, respectively. Eight patients failed initial treatment, and 14 patients relapsed from clinical remission after a median disease-free time of 17 months (range, 6 to 98 months). Median survival time after progression of lymphoma was 5 months (range, 0 to 22 months). In nine (41%) of the 22 failing patients, the initial site of relapse was either the CNS or the contralateral testis; the remaining patients experienced relapse in multiple extranodal sites. Conclusion: Poor pregnosis of patients with diffuse large-cell lymphoma calls for more effective treatment strategies, such as high-dose chemotherapy programs for younger patients or specifically designed chemotherapy regimens for patients not suitable for high-dose treatment, with the purpose to provide control of both systemic disease and disease of the CNS and contralateral testis. The potential benefit of contralateral testicular irradiation has to be taken into account in the treatment planning.

AB - Purpose: To evaluate clinical outcome of patients with testicular diffuse large-cell lymphoma treated with conventional-dose systemic chemotherapy. Patients and Methods: This study is a retrospective analysis of adult patients with testicular diffuse large-cell lymphoma who were treated with a doxorubicin-based chemotherapy regimen at our institution, the Istituto Nazionale Tumori of Milan. Twenty-nine assessable patients, with a median age of 61 years, were identified. Sixteen patients had limited stage (Ann Arbor stage I/II) disease, whereas 13 patients had a testicular mass and distant organ involvement (Ann Arbor stage IV). Patients were retrospectively classified according to the International Prognostic Index. Results: After a median follow-up of 82 months, 22 patients presented disease progression and 22 patients had died. Actuarial median time to treatment failure and overall survival were 44 and 41 months for patients with limited stage and 9 and 16 months for patients with advanced stage, respectively. Eight patients failed initial treatment, and 14 patients relapsed from clinical remission after a median disease-free time of 17 months (range, 6 to 98 months). Median survival time after progression of lymphoma was 5 months (range, 0 to 22 months). In nine (41%) of the 22 failing patients, the initial site of relapse was either the CNS or the contralateral testis; the remaining patients experienced relapse in multiple extranodal sites. Conclusion: Poor pregnosis of patients with diffuse large-cell lymphoma calls for more effective treatment strategies, such as high-dose chemotherapy programs for younger patients or specifically designed chemotherapy regimens for patients not suitable for high-dose treatment, with the purpose to provide control of both systemic disease and disease of the CNS and contralateral testis. The potential benefit of contralateral testicular irradiation has to be taken into account in the treatment planning.

UR - http://www.scopus.com/inward/record.url?scp=0032831012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032831012&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 2854

EP - 2858

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -